HELIX BIOPHARMA CORP. ANNOUNCES EXTENSION OF 2009 WARRANT EXPIRY DATE

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that it has applied to the
Toronto Stock Exchange to extend the expiry date of the 2009 Warrants (as defined below) by six months,
from March 7, 2013 at 5:00 p.m. (Toronto time) (the “Current Expiry Date”) to September 7, 2013 at 5:00
p.m. (Toronto time). Helix previously extended the term of the 2009 Warrants from September 7, 2012 to
the Current Expiry Date. Helix does not propose to amend any other provision of the 2009 Warrants, and
none of the 2009 Warrants is held directly or indirectly by an insider of Helix.

The 2009 Warrants were issued as part of a private placement completed by Helix on September 8, 2009,
pursuant to which Helix issued 6,625,000 units at a subscription price of $2.05 per unit. Each unit consisted
of one common share and one common share purchase warrant (each a “2009 Warrant”), with each 2009
Warrant common entitling the holder to purchase, subject to adjustment, one common share at a price of
$2.87 until the Current Expiry Date.

Subject to the approval of the Toronto Stock Exchange, the expiry date of the 2009 Warrants will be
extended until September 7, 2013 at 5:00 p.m. and will be effective on the 10th business day following the
issuance of this press release.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The
company is actively developing innovative products for the prevention and treatment of cancer based on its
proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the
symbol “HBP”.

Investor Relations:

Helix BioPharma Corp.

Tel: 905 841-2300

Email: ir@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, “forwardlooking statements”) within the meaning of applicable Canadian securities laws, including, without
limitation, forward-looking statements regarding Helix’s proposal to extend the term of the 2009 Warrants.
Forward-looking statements, which may be identified by words including, without limitation, “will” and
other similar expressions, are intended to provide information about management’s current plans and
expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable,
such statements involve risks and uncertainties that may cause actual results or events to differ materially
from those anticipated and no assurance can be given that these expectations will be realized, and undue
reliance should not be placed on such statements. Risk factors that could cause actual results or events to
differ materially from the forward-looking statements include, without limitation, the risk that the approval
of the Toronto Stock Exchange to extend the term of the 2009 Warrants may not be received, and certain of
these risks and uncertainties, and others affecting the company, are more fully described in Helix’s Annual
Information Form, including under the headings “Forward-Looking Statements” and “Risk Factors”, filed
with the Canadian Securities Administrators at www.sedar.com (together, the “Helix Risk Factors”).
Certain material factors or assumptions are applied in making the forward-looking statements, including,
without limitation, the Helix Risk Factors will not cause Helix’s actual results or events to differ materially
from the forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of
Helix’s management on the date of this news release, and Helix does not assume any obligation to update
any forward-looking statement or information should those beliefs, assumptions or expectations, or other
circumstances change, except as required by law.

20130221-HBP-Press-Release-Announced-extension-of-2009-warrants.pdf

Tags:

Jacek Antas

Chief Executive Officer

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

James B. Murphy

Chief Financial Officer

Mr. Murphy is a certified public accountant with over thirty years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC (“Danforth”), a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over fifteen private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over USD 0.5 billion in financing and successfully execute pivotal asset transactions. Mr. Murphy functions as a consultant to Helix pursuant to a consulting agreement between the Company and Danforth.

This will close in 0 seconds

Thomas Mehrling

Medical Adviser

Thomas Mehrling (PhD in Pharmacology and MD) has over 20 years’ experience in multinational Pharma companies developing novel oncology compounds from preclinical research through to registration. Prior to entering the industry, he spent 13 years as an MD at the University Hospital in Frankfurt, working on preclinical and translational projects. He served as Director of European Oncology at Mundipharma International (2003–2013), building the company’s first European oncology business from the ground up out of Cambridge, UK, and completing the clinical development, registration and launch of two major products in Europe, DepoCyte® and Levact® (Ribomustin® and Treanda®). In 2013, he led the establishment of the Mundipharma Group’s start-up, Mundipharma EDO, developing anti-cancer therapeutics for solid tumours out of Basel, Switzerland.

This will close in 0 seconds

Christof Boehler

Chief Business Development Officer

Dr. Christof Boehler is a commercially oriented scientist with a proven track record in building and leading teams that successfully commercialize products and services in the life science industry. His core competencies are in technology transfer, business development and corporate governance with a focus on technology scouting, preclinical and clinical R&D, licensing, sales, capital raising and M&A.

Mr. Boehler is also a strategic advisor to Takeda.

This will close in 0 seconds

Kim Gaspar

Director Quality Assurance

Kim is the Director of Quality Assurance at Helix BioPharma Corp. An experienced quality assurance professional with expertise in Canadian, US, and EU regulations, she has been involved in all aspects of Phase I/II biopharmaceutical product development over the years, including regulatory submissions, QC laboratory compliance, tech transfer and third-party oversight of CMC activities, clinical QA, and bioanalytical data analysis. Kim joined Helix in 2000, transitioning into QA in 2003. She holds a B.Sc in Biochemistry and a Ph.D in Veterinary Physiological Sciences, both from the University of Saskatchewan.

This will close in 0 seconds

Brenda Lee

Director Clinical Operations

Brenda is the Clinical Operations Director at Helix Biopharma Corp. A clinical research operations professional with 25 years of experience managing clinical trials, ranging from early Phase I to late Phase IIIb/IV studies, she brings experience in clinical study protocol writing and development, trial start-up and vendor management, and a proven track record in planning and managing clinical trials to quality standards, timelines and budget. Brenda joined Helix Biopharma Corp. in 2018, working to advance the clinical program of L-DOS47. She holds B.Sc and M.Sc. degrees from the University of Toronto, specializing in Nutritional Sciences and Human Biology.

This will close in 0 seconds

Praveen Kumar

V.P. Drug Development

Praveen has experience working in the pharmaceutical industry for more than 25 years and has expertise in the development of drug products for small and macro-molecules using various dosage forms. He was involved in projects comprising the formulation development of generic drug products and their production and developed a novel transdermal drug product containing a protein-based drug (interferon alpha 2b) for the treatment of HPV infections.

Presently as a V.P. he manages the CMC-related activities (drug product formulation, technology transfer, quality, stability testing and interaction with regulatory agency) for the development of L-DOS47 drug product, an antibody drug conjugate, for the treatment of various cancers. He has a Ph.D. in Pharmaceutical sciences and he completed his post-doctoral fellowship in gene regulation. He was the author of multiple peer-reviewed published articles, a book chapter, and patents.

This will close in 0 seconds

Jerzy Leszczynski

Director

Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Master of Science in Chemistry from the Warsaw Institute of Technology.

This will close in 0 seconds

Janusz Grabski

Director, Chair of Audit Committee

Janusz (John) Grabski is a lawyer specialized in corporate and real estate law with over twenty years of experience.

This will close in 0 seconds

Malgorzata Laube

Director

Malgorzata Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology and is based in Edmonton, Alberta, Canada.

This will close in 0 seconds

Jacek Antas

Chairman of the Board

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds